Dutch health technology company Royal Philips (NYSE:PHG) (AEX:PHIA) announced on Thursday that it has launched the Philips ECG AI Marketplace, a centralised platform designed to streamline access to artificial intelligence solutions for cardiac diagnostics.

The platform is designed to enable healthcare providers to integrate multiple AI tools into existing Philips systems, improving efficiency and care delivery.

The Marketplace is aimed at reducing the operational burden of managing multiple AI tools by centralising vendor connections, thereby lowering IT costs and accelerating diagnostic workflows. It also allows US hospitals to implement validated AI tools at the point of care, enhancing clinical decision-making.

Anumana, Inc., an AI-focused health technology company, is the first third-party vendor to offer a solution through the platform. Its FDA-cleared ECG-AI LEF (Low Ejection Fraction) algorithm, designed to detect early signs of heart failure from standard ECGs, is now accessible via Philips' ECG portfolio, including the IntelliSpace ECG and Philips cardiographs.

Anumana stated that its AI algorithms have been validated in studies involving over 150,000 patients and supported by nearly 100 peer-reviewed publications. The company plans to introduce additional AI tools through the Marketplace as they receive FDA clearance.